Singapore - English - HSA (Health Sciences Authority)

abbvie pte. ltd. - upadacitinib hemihydrate eqv upadacitinib - tablet, film coated, extended release - upadacitinib hemihydrate eqv upadacitinib 15mg

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - elagolix as sodium - film coated tablets - elagolix as sodium 150 mg - elagolix - orilissa is indicated for the management of moderate to severe pain associated with endometriosis.

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - elagolix as sodium - film coated tablets - elagolix as sodium 200 mg - elagolix - orilissa is indicated for the management of moderate to severe pain associated with endometriosis.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

abbvie sdn bhd - upadacitinib hemihydrate -

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - upadacitinib as hemihydrate - tablets prolonged release - upadacitinib as hemihydrate 30 mg - upadacitinib - atopic dermatitis rinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Singapore - English - HSA (Health Sciences Authority)

abbvie pte. ltd. - upadacitinib hemihydrate eqv upadacitinib - tablet, film coated, extended release - upadacitinib hemihydrate eqv upadacitinib 30mg

Singapore - English - HSA (Health Sciences Authority)

abbvie pte. ltd. - upadacitinib hemihydrate eqv upadacitinib - tablet, film coated, extended release - upadacitinib hemihydrate eqv upadacitinib 45mg

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - risankizumab - solution for injection - risankizumab 150 mg/ml - risankizumab - skyrizi is indicated for the treatment of patients 16 years and older with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy, or if such therapies are not advisable.

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - risankizumab - concentrate for solution for infusion - risankizumab 60 mg/ml - risankizumab - skyrizi is indicated for the treatment of patients 16 years and older with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy, or if such therapies are not advisable.

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - upadacitinib as hemihydrate - tablets prolonged release - upadacitinib as hemihydrate 45 mg - upadacitinib - ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.